Heritage, Apotex settlements with end payers get final nod in US generic drug case
MLex Summary: Heritage Pharmaceuticals and Apotex’s settlements with end-payer plaintiffs have been granted final approval to resolve US price-fixing claims over generic pharmaceuticals. Under the deals, Heritage will pay $10 million,...To view the full article, register now.
Already a subscriber? Click here to view full article